IMMX Archives - Spark Newswire

2 minute read

Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In AL Amyloidosis

February 7, 10:41 AM

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU protocol assistance,

IMMX

1 minute read

Immix Biopharma Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed

By Benzinga Newsdesk

February 5, 4:21 PM

Immix Biopharma, Inc. (NASDAQ:IMMX) (the "Company"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common

IMMX

4 minute read

Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Avi Kapoor

January 25, 3:52 PM

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.

AAL

1 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

January 25, 1:31 PM

Gainers Onconetix (NASDAQ:ONCO) stock rose 161.5% to $0.39 during Thursday’s regular session. The market value of their outstanding…

AFIB

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

December 15, 1:31 PM

Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) stock rose 57.8% to $0.38 during Friday’s regular session. The market value of their…

AADI

1 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

December 14, 1:32 PM

Gainers TriSalus Life Sciences (NASDAQ:TLSI) stock moved upwards by 38.3% to $8.23 during Thursday’s regular session. The market…

APLS

4 minute read

Immix Biopharma Announces 100% Overall Response Rate And 70% Complete Response; 23.7 Months Best Response Duration (Ongoing) For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis Patients At ASH 2023

By Benzinga Newsdesk

December 11, 10:39 AM

100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated

IMMX

3 minute read

Immix Biopharma Announces FDA Approval Of IND Application For CAR-T NXC-201, Enabling U.S. Patient Dosing

By Benzinga Newsdesk

November 21, 10:46 AM

NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain (AL)

IMMX

3 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

October 23, 1:31 PM

Gainers INVO Bioscience (NASDAQ:INVO) stock moved upwards by 361.1% to $2.49 during Monday’s regular session. Trading volume for…

ABVC

1 minute read

What’s Going On With Cancer-Focused Immix Biopharma Stock Today?

By Vandana Singh

October 2, 2:25 PM

Immix Biopharma Inc (NASDAQ: IMMX) announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 study of its NXC-201, an autologous, BCMA-targeted chimeric antigen receptor T

IMMX

Feed Symbols: IMMX